Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study [version 2; peer review: 2 approved]

Background: Lateral flow immunoassays (LFIAs) are able to achieve affordable, large scale antibody testing and provide rapid results without the support of central laboratories. As part of the development of the REACT programme extensive evaluation of LFIA performance was undertaken with individuals...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Maria Prendecki, Tina Thomson, Anjna Badhan, Maya Moshe, Bob Klaber, Bryony Simmons, Sarah Gleeson, Ara Darzi, Michelle Willicombe, Paul Martin, Graham S. Cooke, Peter Kelleher, Steven Riley, Deborah Ashby, Wendy S. Barclay, Helen Ward, Paul Elliott, Alexandra Cann, Jonathan Brown, Candice Clarke
Format:	Artigo
Jezik:	Inglês
Izdano:	Wellcome 2022-05-01
Serija:	Wellcome Open Research
Teme:	SARS-CoV-2 Covid-19 Lateral flow LFIA Antibodies Neutralisation eng
Online dostop:	https://wellcomeopenresearch.org/articles/6-358/v2
Oznake:	Označite Brez oznak, prvi označite!